Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis

Company Overview

Acura Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products designed to deter prescription drug abuse and misuse. The company’s core business centers on proprietary drug formulations that incorporate its Aversion and ARCUS® abuse-deterrent technologies. These platforms are intended to make it more difficult to tamper with or extract active pharmaceutical ingredients from oral dosage forms, helping to address public health concerns around opioid and stimulant abuse.

Acura’s lead product, Oxaydo®, is an immediate‐release oxycodone tablet that employs Aversion® technology to discourage tampering and intravenous abuse. In addition to Oxaydo®, the company has advanced a pipeline of collaborative research agreements with other pharmaceutical partners seeking to integrate Acura’s intellectual property into their own opioid and stimulant portfolios. Acura’s ARCUS® technology further expands its offerings by providing a nasal discomfort mechanism designed to deter intranasal abuse of solid dosage forms.

Founded in 2001 and headquartered in Palatine, Illinois, Acura Pharmaceuticals serves markets across the United States and has established licensing relationships with both branded and generic drug manufacturers. The company operates under the leadership of an executive team with experience in pharmaceutical development, regulatory affairs and commercial strategy. Acura continues to pursue regulatory approvals, strategic collaborations and intellectual property development aimed at reducing the societal impact of prescription drug abuse.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.75
• Volume: N/A
• Average Volume: 3,247 shs
• Market Capitalization: $13.30 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACUR Stock Analysis - Frequently Asked Questions

How have ACUR shares performed this year?

Acura Pharmaceuticals' stock was trading at $0.0002 at the beginning of the year. Since then, ACUR stock has increased by 0.0% and is now trading at $0.0002.

How were Acura Pharmaceuticals' earnings last quarter?

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) announced its quarterly earnings data on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 earnings per share for the quarter. The specialty pharmaceutical company had revenue of $1.32 million for the quarter.

Does Acura Pharmaceuticals have any subsidiaries?

The following companies are subsidiaries of Acura Pharmaceuticals: Acura Pharmaceutical Technologies Inc..

How do I buy shares of Acura Pharmaceuticals?

Shares of ACUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Acura Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acura Pharmaceuticals investors own include Denali Therapeutics (DNLI), Ekso Bionics (EKSO), VIVUS (VVUS), Corbus Pharmaceuticals (CRBP), Fulcrum Therapeutics (FULC) and Adamis Pharmaceuticals (ADMP).

Company Calendar

• Last Earnings: 2/28/2020
• Today: 9/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ACUR
• Previous Symbol: NASDAQ:ACUR
• CIK: 786947
• Web: www.acurapharm.com
• Phone: (847) 705-7709
• Fax: 847-705-5399
• Employees: 10
• Year Founded: 1935

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 66,500,000
• Free Float: 53,066,000
• Market Cap: $13.30 thousand
• Optionable: Not Optionable
• Beta: -1.95